迪哲医药-U
(688192)
| 流通市值：234.94亿 | | | 总市值：236.96亿 |
| 流通股本：4.61亿 | | | 总股本：4.65亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 252,521,933.82 | 801,135,558.29 | 586,301,134.9 | 355,001,420.82 |
| 营业收入 | 252,521,933.82 | 801,135,558.29 | 586,301,134.9 | 355,001,420.82 |
| 二、营业总成本 | 365,009,076.26 | 1,654,178,465.58 | 1,234,483,936.24 | 779,607,061.37 |
| 营业成本 | 10,290,501.15 | 34,228,877.37 | 25,325,157.63 | 15,627,388.07 |
| 税金及附加 | 981,427.79 | 3,203,005.35 | 2,204,553.79 | 1,181,663.24 |
| 销售费用 | 124,486,649 | 570,792,086.75 | 423,739,702.55 | 268,437,718.75 |
| 管理费用 | 34,324,794.44 | 160,154,685.31 | 116,279,108.6 | 69,705,766.61 |
| 研发费用 | 187,797,243.72 | 855,608,765.67 | 644,235,609.66 | 408,267,006.28 |
| 财务费用 | 7,128,460.16 | 30,191,045.13 | 22,699,804.01 | 16,387,518.42 |
| 其中:利息费用 | 7,595,979.38 | 31,215,788.09 | 23,591,119.1 | 17,152,091.02 |
| 其中:利息收入 | -287,488.87 | 2,136,412.46 | 1,840,889.36 | 1,459,518.03 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,753,808.85 | 25,326,758.27 | 18,554,239.98 | 11,219,000.56 |
| 资产处置收益 | - | 279.52 | 279.52 | 279.52 |
| 信用减值损失(新) | -278,273 | -1,171,167.94 | -1,006,159.94 | -551,953.94 |
| 其他收益 | 9,645,182.39 | 62,524,314.13 | 47,733,361.57 | 34,947,986.41 |
| 四、营业利润 | -96,366,424.2 | -766,362,723.31 | -582,901,080.21 | -378,990,328 |
| 加:营业外收入 | 24,435 | - | - | - |
| 减:营业外支出 | 314.61 | 763,990.11 | - | - |
| 五、利润总额 | -96,342,303.81 | -767,126,713.42 | -582,901,080.21 | -378,990,328 |
| 减:所得税费用 | 359,901.2 | 1,390,731.26 | 52,072.14 | 52,072.14 |
| 六、净利润 | -96,702,205.01 | -768,517,444.68 | -582,953,152.35 | -379,042,400.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -96,702,205.01 | -768,517,444.68 | -582,953,152.35 | -379,042,400.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -95,557,355.51 | -764,049,492.71 | -579,947,780.97 | -377,360,125.54 |
| 少数股东损益 | -1,144,849.5 | -4,467,951.97 | -3,005,371.38 | -1,682,274.6 |
| 扣除非经常损益后的净利润 | -108,832,550.09 | -841,553,000.77 | -630,660,904.63 | -419,231,317.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.21 | -1.71 | -1.32 | -0.87 |
| (二)稀释每股收益 | -0.21 | -1.71 | -1.32 | -0.87 |
| 九、综合收益总额 | -96,702,205.01 | -768,517,444.68 | -582,953,152.35 | -379,042,400.14 |
| 归属于母公司股东的综合收益总额 | -95,557,355.51 | -764,049,492.71 | -579,947,780.97 | -377,360,125.54 |
| 归属于少数股东的综合收益总额 | -1,144,849.5 | -4,467,951.97 | -3,005,371.38 | -1,682,274.6 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |